This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognizing you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.
Experts
Daniel Weinberg
Vice President
Contact
DanielWeinberg@westat.comOverview
Daniel Weinberg, PhD, MBA, joined Westat in June 2021 as a Vice President for Behavioral Health and Health Policy. He is a seasoned health economist with expertise in health care payment policy and innovative payment and delivery models. Most recently, Weinberg has focused on leading operations, implementation, and monitoring work to support alternative payment models with the Centers for Medicare & Medicaid Services (CMS) Innovation Center (the Center for Medicare & Medicaid Innovation [CMMI]). Weinberg has applied rigorous quasi-experimental approaches to evaluate the impact of payment system and care delivery reforms on quality, cost, and patient outcomes. He will oversee large, complex health services research projects, lead CMS implementation and evaluation efforts, and maintain and enhance client relationships.
Education
- PhD, Economics, University of Florida
- MA, MBA, Economics, University of Illinois – Chicago
-
Incomplete cytoreduction of colorectal cancer peritoneal metastases: Survival outcomes by a cytoreduction score
38,
Visceral Medicine
January 2022
P.H. Sugarbaker, D. Chang
DOILink for: Incomplete cytoreduction of colorectal cancer peritoneal metastases: Survival outcomes by a cytoreduction score -
Multi-laboratory evaluation of the Illumina iSeq platform for whole genome sequencing of salmonella, escherichia coli and listeria
8,
Microbial Genomics
January 2022
P.K. Mitchell, L. Wang, B.J. Stanhope, B.D. Cronk, R. Anderson, S. Mohan, L. Zhou, et al.
DOILink for: Multi-laboratory evaluation of the Illumina iSeq platform for whole genome sequencing of salmonella, escherichia coli and listeria -
Waning 2-dose and 3-dose effectiveness of mRNA vaccines against COVID-19-associated emergency department and urgent care encounters and hospitalizations among adults during periods of Delta and Omicron varia
71,
Morbidity and Mortality Weekly Report
January 2022
J.M. Ferdinands, S. Rao, B.E. Dixon, P.K. Mitchell, M.B. DeSilva, S.A. Irving, N. Lewis, et al.
DOILink for: Waning 2-dose and 3-dose effectiveness of mRNA vaccines against COVID-19-associated emergency department and urgent care encounters and hospitalizations among adults during periods of Delta and Omicron varia